secwatch.observer — SEC 8-K summary
======================================

Issuer:     CDT Equity Inc. (CDT)
CIK:        0001896212
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0001641172-25-002774
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares
--------------------------------------------------------------------------------

- Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.
- Agreement term six months, total consideration $2.0M (cash or stock at company's election).
- Issued 1,853,933 shares to satisfy ~$1.65M of fees; also issued 410,113 shares for consulting services.
- Company had 9,549,800 shares outstanding as of March 31, 2025.
- Aim is to re-evaluate failed endpoints from AstraZeneca trials to identify benefited patient subgroups.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1896212/000164117225002774/0001641172-25-002774-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1896212/000164117225002774/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-002774

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer